Current Issues in Molecular BiologyRespiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj +2 more sources
Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis [PDF]
Frontiers in Public HealthBackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani +8 more
doaj +2 more sources
Evaluation of nirsevimab against rsv infection in infants
, 2023 19 p.ill.,LIST OF TABLES 1 -- BACKGROUND 3 -- 1 BACKGROUND 4 -- 2 METHODS 4 -- 3 CLINICAL EVIDENCE 7 -- 3.1 NIRSEVIMAB IN PRETERM INFANTS 7 -- 3.2 NIRSEVIMAB IN LATE-PRETERM AND TERM INFANTS 9 -- 3.3 MEDLEY TRIAL 14 -- 3.4 HARMONIE TRIAL (PRELIMINARY ...
Desimpel, Fabian
core +1 more source
Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children [PDF]
Clinical and Experimental PediatricsRespiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal ...
Soo-Han Choi +15 more
doaj +1 more source
Impact of Nirsevimab on Respiratory Syncytial Virus PCR Test Positivity in Young Infants: A Community-Level Observational Study in Queensland, Australia. [PDF]
J Paediatr Child HealthABSTRACT Aim In April 2024 nirsevimab, a long‐acting respiratory syncytial virus (RSV)‐specific monoclonal antibody, was made available free of charge to all newborn infants in Queensland. We aimed to explore the community‐level impact of a nirsevimab‐based prevention program on RSV detection percentages among infants aged ≤ 3 months in Queensland ...
El-Heneidy A +6 more
europepmc +2 more sources
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales [PDF]
, 2022 INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease.
Koltai, Mihaly +6 more
core +1 more source
EClinicalMedicineSummary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary +10 more
doaj +1 more source
Expert Review of VaccinesBackground Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan.
Naruhiko Ishiwada +6 more
doaj +1 more source
First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants [PDF]
Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May.
Scarpaleggia M. +20 more
core +3 more sources
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
, 2023 International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach +31 more
core +1 more source